OncoSec Medical Inc (ONCSQ)

[lasers]

ahab333 31 Patients is excellent for a Phase2A for safety and tolerability. Results will be reported after 1 year in 2016 and followup 2nd year into 2017. Also perhaps there could likely be a 6 month interim results end of 2015.

Primary Outcome Measures: •Best overall response rate (BORR) by RECIST v1.1 [ Time Frame: 1 year ] [ Designated as safety issue: No ]


Secondary Outcome Measures: •Safety and tolerability of pIL-12 EP (assessed through adverse events graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0) [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]